The Aporia
Everett, B. (2026, November 17). Trump administration weighs Marshall for FDA as Overton wobbles. Semafor. https://www.semafor.com/article/11/17/2026/republicans-consider-marshall-a-viable-fda-pick-as-overton-wobbles
Everett, Burgess. “Trump administration weighs Marshall for FDA as Overton wobbles.” Semafor, 17 Nov. 2026, https://www.semafor.com/article/11/17/2026/republicans-consider-marshall-a-viable-fda-pick-as-overton-wobbles.
Everett, Burgess. “Trump administration weighs Marshall for FDA as Overton wobbles.” Semafor, November 17, 2026. https://www.semafor.com/article/11/17/2026/republicans-consider-marshall-a-viable-fda-pick-as-overton-wobbles.
Dated from the outlet's own feed. Check the original for its byline.
As of November 17, 2026, the Trump administration is considering Roger Marshall, a Kansas Republican and former physician, as a potential replacement for Heidi Overton to lead the Food and Drug Administration (FDA). Overton's confirmation is facing significant challenges due to opposition from both anti-abortion activists and moderate Republicans. The Senate health committee is scheduled to vote on Overton’s nomination on November 15, but her path to confirmation is seen as exceedingly difficult. Republicans are under pressure to confirm Trump’s nominees before their majority expires in a month and a half. Marshall, who just lost his reelection bid, is viewed as a stronger nominee because senators generally have an easier time getting confirmed compared to other candidates. It is not clear how quickly the administration will move on an alternative nominee if Overton’s nomination fails.